文献速递艾滋病与性传播感染

病毒学病史可预测长效卡博特韦联合利匹韦林治疗下病毒抑制非持续,且独立于药代动力学参数

Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters.
PubMed 文献 · Clin Infect Dis · 2025-01-01

一项前瞻性队列研究纳入173例从稳定口服抗逆转录病毒治疗转换为每两月一次长效卡博特韦联合利匹韦林注射的HIV感染者,中位随访11.1个月。38.7%出现病毒载量≥20拷贝/mL,16.2%≥50拷贝/mL,间歇性病毒血症34.7%,持续性低水平病毒血症4%,病毒学失败2例。非持续病毒抑制的预测因素包括HIV诊断时病毒载量、口服治疗期间可检测病毒血症及转换时病毒抑制水平,且独立于药代动力学参数。

要点

  • 转换时病毒抑制水平越高,非持续病毒抑制风险越低(AHR 0.38)。
  • HIV诊断时病毒载量每增加1 log10,风险增加(AHR 1.49)。
  • 口服治疗期间可检测病毒血症者风险升高(AHR 2.45)。

核心结论

  • 从稳定口服抗逆转录病毒治疗转换为长效卡博特韦联合利匹韦林治疗的HIV感染者中,病毒抑制非持续与转换前存在的因素相关,且独立于药代动力学参数。

研究设计与样本

  • 前瞻性队列研究,纳入173例从稳定口服抗逆转录病毒治疗转换为每两月一次长效卡博特韦联合利匹韦林注射的HIV感染者,中位随访11.1个月(IQR 7.1-13.2),共789次给药前浓度测量。

主要发现

  • 38.7%的患者出现病毒载量≥20拷贝/mL,16.2%出现≥50拷贝/mL。
  • 间歇性病毒血症发生于34.7%的患者,持续性低水平病毒血症发生于4%,病毒学失败2例。
  • 非持续病毒抑制的预测因素包括:HIV诊断时病毒载量(AHR 1.49/每log10病毒载量,95%CI 1.04-2.12,P=0.027)、口服抗逆转录病毒治疗期间可检测病毒血症(AHR 2.45,95%CI 1.29-4.65,P=0.006)、转换时病毒抑制水平(AHR 0.38,95%CI 0.19-0.75,P=0.004)。
  • 卡博特韦和利匹韦林低谷浓度与病毒载量≥50拷贝/mL的检测到病毒血症发作显著相关,但在多变量模型中,所评估的药代动力学协变量均未预测非持续病毒抑制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aimed to investigate factors contributing to non-sustained viral suppression, including intermittent viremia and persistent low-level viremia, during cabotegravir (CAB) plus rilpivirine (RPV) long-acting (LA) injectable therapy, with a focus on pharmacokinetics (PK). METHODS: A prospective cohort study was conducted on people with human immunodeficiency virus (HIV, PWH) transitioning from stable oral antiretroviral therapy (ART) to bimonthly CAB + RPV LA. Standardized follow-up included close monitoring through blood sampling for plasma human immunodeficiency virus type 1 (HIV-1) viral load (VL) and multiple plasma drug concentrations measurements to analyze the connection between PK parameters and virologic outcomes. RESULTS: Among 173 patients with a median (interquartile range [IQR]) follow-up of 11.1(7.1-13.2) months and 789 pre-dose measurements, 38.7% experienced VL ≥ 20 copies/mL, and 16.2% had levels ≥50 copies/mL. Intermittent viremia occurred in 34.7% of patients, and persistent low-level viremia in 4%. Virological failure developed in 2 cases. Predictors of non-sustained viral suppression included VL at HIV diagnosis (adjusted hazard ratio [AHR]: 1.49 per log10 VL, 95% confidence interval [CI]: 1.04-2.12, P = .027), detectable viremia on oral ART (AHR: 2.45, 95% CI: 1.29-4.65, P = .006), and the level of viral suppression at transition (AHR: 0.38, 95% CI: .19-.75, P = .004). We found a significant association between low trough concentrations of CAB and RPV and episodes of detectable viremia exceeding 50 copies/mL. However, none of the assessed PK covariates predicted non-sustained viral suppression in multivariable models. CONCLUSIONS: Non-sustained viral suppression in PWH transitioning from stable oral ART to CAB + RPV LA was linked to preexisting factors before transition. Higher VL pre-ART and incomplete suppression on oral therapy increased the risk, independent of PK parameters.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Gutiérrez F, Fernández-González M, Ledesma C, et al. Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters. Clin Infect Dis. 2025. PMID: 39298641. doi:10.1093/cid/ciae475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。